Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM70BU5)

Drug Name
Thalidomide Drug Info
Synonyms
Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
Indication
Disease Entry ICD 11 Status REF
Adult T-cell leukemia/lymphoma Approved [1]
Advanced cancer 2A00-2F9Z Approved [1]
Complex regional pain syndrome type 1 Approved [1]
Hepatosplenic T-cell lymphoma Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Leukemia Approved [1]
MALT lymphoma Approved [1]
Multiple myeloma 2A83 Approved [2]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Pain MG30-MG3Z Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified Approved [1]
Prolymphocytic leukaemia 2A82.1 Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma Approved [1]
Splenic marginal zone lymphoma Approved [1]
Testicular lymphoma Approved [1]
Urinary bladder neoplasm Approved [1]
Waldenstrom macroglobulinemia 2A85.4 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
Colon cancer 2B90.Z Investigative [1]
Therapeutic Class
Immunosuppressive Agents
Cross-matching ID
PubChem CID
5426
ChEBI ID
CHEBI:74947
CAS Number
CAS 50-35-1
TTD Drug ID
DM70BU5
VARIDT Drug ID
DR00461
INTEDE Drug ID
DR1572
ACDINA Drug ID
D00669

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Inhibitor [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Approved [5]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Approved [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Approved [7]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Approved [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Approved [9]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Approved [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Approved [6]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Approved [5]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Approved [6]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tumor necrosis factor (TNF) DTT TNF 5.692 3.07 4.413 1.202
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 8.485 5.28 4.621 8.889
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 12.054 3.968 2.945 4.1
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 9.791 3.744 3.413 1.609
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 10.644 6.631 6.598 6.937
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 10.08 7.207 5.403 9.211
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.867 5.142 5.52 7.08
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 11.76 5.931 6.164 9.423
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 6.09 7.747 6.04 7.023
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Adult T-cell leukemia/lymphoma
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 8.64E-01 -0.06 -0.16
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 6.01E-02 4.39E-01 1.83E+00
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 8.20E-01 3.19E-02 1.66E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 9.63E-01 1.10E-01 2.91E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 8.91E-01 -3.14E-02 -1.42E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 1.23E-01 2.71E-01 8.39E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.47E-02 -1.30E+00 -1.39E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 5.67E-01 -4.03E-02 -2.13E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.00E-01 3.06E-02 1.84E-01
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 1.71E-02 7.25E-01 2.30E+00
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Thalidomide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7327).
3 ClinicalTrials.gov (NCT04273529) The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia. U.S. National Institutes of Health.
4 Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
5 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
6 Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
7 Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.
8 Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
9 Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem Res Toxicol. 2010 Jun 21;23(6):1018-24.